🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Stage IIIA Non-small Cell Lung Cancer

Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487n/a17 sites📍 A Coruña📍 Alicante📍 Badalona Fundación GECP · Tests: Cisplatin, Carboplatin Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342Phase 23 sites📍 Beijing📍 Guangzhou📍 Zhejiang Jianxing He · Tests: fulzerasib Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) NCT07154706Phase 333 sites📍 Los Angeles📍 Orange📍 Washington D.C. Nuvation Bio Inc. · Tests: Taletrectinib, Placebo Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites📍 Ferrol📍 Alicante📍 Badalona Fundación GECP · Tests: Durvalumab Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) NCT07153445Phase 221 sites📍 Alicante📍 Badalona📍 Barcelona Fundación GECP · Tests: Atezolizumab, Paclitaxel, Carboplatin Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC NCT06810609Phase 25 sites📍 Freiburg im Breisgau📍 Stuttgart📍 Giessen University Hospital, Bonn · Tests: surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance… Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation NCT05010109NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: 6 Minute Walk Functional Test, Biospecimen Collection, Computed Tomography, Echocardiography, Exercise Cardiac Stress T… Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. NCT06492421Phase 21 site📍 Guanzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients NCT06987734Phase 21 site📍 Shanghai Shanghai Pulmonary Hospital, Shanghai, China · Tests: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery NCT07182682Phase 349 sites📍 Beijing📍 Beijing📍 Beijing Dizal (Jiangsu) Pharmaceutical Co., Ltd. · Tests: sunvozertinib, Matching Placebo ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC NCT06426511Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer NCT05136846Phase 12 sites📍 Duarte📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Carboplatin, Durvalumab, Paclitaxel, Papaverine, Radiation Therapy Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy NCT04892953Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC NCT07554846Phase 31 site📍 Shanghai Fudan University · Tests: Peroperative immunotherapy, Neoadjuvant immunotherapy, Adjuvant immunotherapy Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers NCT03948100NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Educational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Yoga To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT04853342Phase 31 site📍 Suzhou Allist Pharmaceuticals, Inc. · Tests: Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo Using Urine Samples to Identify Lung Cancer NCT06033248n/a7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: urine sample Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC NCT06241807Phase 21 site📍 Jinan Shandong Cancer Hospital and Institute · Tests: Camrelizumab Plus Chemotherapy Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery NCT06109454n/a1 site📍 Shenyang Liaoning Cancer Hospital & Institute · Tests: Huaier granule, Control Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study NCT05802186NA1 site📍 Chicago Northwestern University · Tests: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Radiology, T… D-BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC NCT07016126Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: D-BACE in combination with chemotherapy and karelizumab To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy NCT06192849Phase 21 site📍 Chengdu Juan LI, MD · Tests: Furmonertinib Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors NCT05269381Phase 1, Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab, Sargramostim, Biospecimen Collection Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer NCT03819296Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer NCT05798845Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: SBRT+LDRT, Toripalimab, Chemotherapy drug, Toripalimab Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial NCT06498635Phase 3281 sites📍 Jonesboro📍 Beverly Hills📍 Dublin National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse NCT05732974n/a1 site📍 Toulouse University Hospital, Toulouse · Tests: Resected non small cell lung cancer Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC NCT04865250Phase 21 site📍 Heidelberg University Hospital Heidelberg · Tests: Atezolizumab 1200 mg abs day 1 q22 (iv) Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer NCT05241028Phase 21 site📍 Shijiazhuang Hebei Medical University Fourth Hospital · Tests: Ensartinib A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy NCT06931717Phase 335 sites📍 Vienna📍 Talinn📍 Angers ETOP IBCSG Partners Foundation · Tests: Cemiplimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy